Thomas Nahde is the global head of harm reduction and engagement at Imperial Brands. He leads the scientific substantiation of Imperial’s next-generation product (NGP) portfolio as the business seeks to make a meaningful contribution to tobacco harm reduction. Nahde oversees a multidisciplinary team, which conducts NGP scientific research as well as educating, engaging and communicating the scientific results to a broad range of internal and external stakeholders.
Nahde is passionate about translating complex scientific research into meaningful health outcomes that benefit consumers and inspiring and developing others through empathetic and authentic leadership. Nahde holds a Ph.D. in biomedical science and has previously held senior medical education and medical affairs roles at Smith and Nephew and GlaxoSmithKline Consumer Healthcare.
